Thelansis

 Lymphangioleiomyomatosis (LAM), a rare multisystem disorder primarily impacting women, may manifest sporadically or in conjunction with tuberous sclerosis. The gradual replacement of lung parenchyma with cysts results in symptoms such as dyspnea, recurrent pneumothorax, and, in severe cases, respiratory failure. Patients may also experience lymphatic involvement in the thorax, abdomen, pelvis, and renal angiomyolipomas. Treatment strategies encompass supportive measures, bronchodilators, and, for progressive cases, mammalian targets of rapamycin (mTOR) inhibitors. LAM is typically caused by mutations in the TSC1 or, more frequently, the TSC2 gene. ·        Lymphangioleiomyomatosis affects approximately 3.3 to 7.4 per million women globally.   Thelansis’s “Lymphangioleiomyomatosis (LAM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, pres...

Lymphangioleiomyomatosis (LAM) is a condition that affects the lungs, kidneys, and lymphatic system of women of childbearing age. Mutations in the TSC1 gene or, more commonly, the TSC2 gene cause LAM. ·        Lymphangioleiomyomatosis (LAM) affects 3.3 to 7.4 per million women worldwide. Thelansis’s “Lymphangioleiomyomatosis (LAM) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lymphangioleiomyomatosis (LAM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Lymphangioleiomyomatosis (LAM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insi...